| Hilary Hayashi Spannagel, | |
|
1929 Main St Ste 103, Irvine, CA 92614-6524 | |
| (949) 229-5709 | |
| Not Available |
| Full Name | Hilary Hayashi Spannagel |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 1929 Main St Ste 103, Irvine, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013401819 | NPI | - | NPPES |
| 27923 | Other | CA | SPEECH PATHOLOGIST LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 27923 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Hilary Hayashi Spannagel, 113 Costero Aisle, Irvine, CA 92614-5943 Ph: (310) 927-4894 | Hilary Hayashi Spannagel, 1929 Main St Ste 103, Irvine, CA 92614-6524 Ph: (949) 229-5709 |
News Archive
In diverse ecosystems, packed with wildly different species, evolution whizzes along. As different species accumulate mutations, some adapt particularly well to their environment and prosper.
Antidepressants can play a key role in alleviating painful conditions like osteoarthritis and may result in fewer side effects than traditionally prescribed drug regimes, such as anti-inflammatories and opioids, according to a perspective paper published online ahead of print publication by the International Journal of Clinical Practice.
Chemist Jin-Quan Yu of The Scripps Research Institute (TSRI) has won a 2016 MacArthur Fellowship, sometimes called a "genius grant."
BioMimetic Therapeutics, Inc. announced today the Canadian Intellectual Property Office (CIPO) has allowed patent application No. 2,583,823 titled "Platelet Derived Growth Factor (PDGF) Compositions and Methods of Use Thereof". The new patent will remain in force until October 2025, during which time it will prohibit the marketing of similar or generic versions of the Company's Augment™ orthopedic product line and certain other rhPDGF-BB product formulations.
In a trial of 426 patients with Type 2 diabetes, TAK-875 reduced blood sugar below a pre-determined level in as much as 48 percent of those receiving it after 12 weeks, compared with 40 percent of those who took glimepiride, the older drug, according to findings published online by The Lancet medical journal. The research was presented in June at the American Diabetes Association's annual meeting in San Diego.
› Verified 4 days ago
Ms. Linda Charley Hill, M.A. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 18 Hillgrass, Irvine, CA 92603 Phone: 949-233-0219 | |
Adrienne Rzepnick, MA CCC Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 18017 Sky Park Cir Ste G, Irvine, CA 92614 Phone: 949-929-5465 Fax: 949-737-1777 | |
Ms. Laura Adjunta, M.A. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 13143 Spectrum, Irvine, CA 92618 Phone: 510-646-6304 | |
Mrs. Natalia M Guarino, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3301 Ansel, Irvine, CA 92618 Phone: 407-432-2866 | |
Leora Shaffer, MA CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4010 Barranca Pkwy Ste 220, Irvine, CA 92604 Phone: 949-857-6051 | |
Mrs. Stacie Christine Carrell, STACIE BATEMAN Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 46 Orange Blossom, Irvine, CA 92618 Phone: 714-943-4944 Fax: 949-271-4941 |